New Benchmarks in Acid-Related Disorders: A Debate With the Experts

A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.

To view the supplement, click the image above.

INTRODUCTION
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Centre
Hamilton, Ont.
Consultant: Abbott Laboratories, Axcan Pharma Inc., AstraZeneca, Merck & Co., Novartis Pharmaceuticals Corp., Procter & Gamble Co., TAP Pharmaceutical Products, Inc.; Investigator: Axcan, AstraZeneca, Merck, TAP.

USE OF NONSELECTIVE NSAIDS, CYCLOOXYGENASE INHIBITORS, AND PROTON PUMP INHIBITORS
Treat With Nonselective NSAIDs, plus PPIs
Michael B. Kimmey, MD
Professor of Medicine and Director of Gastrointestinal Endoscopy
University of Washington
Seattle, WA
Nothing to disclose.

Treat With Cyclooxygenase Inhibitors
Jay L. Goldstein, MD
Professor of Medicine
Vice Head for Clinical Affairs
Department of Medicine
University of Illinois
Chicago, IL
Consultant & Grant Support: AstraZeneca, Pharmacia Corp., Pfizer Inc., TAP.

OPTIONS IN THE LONG-TERM MAINTENANCE OF GASTROESOPHAGEAL REFLUX DISEASE
Endoscopic/Surgical Intervention
George Triadafilopoulos, MD
Professor of Medicine
Stanford University School of Medicine
Chief, Section of Gastroenterology
Palo Alto Veterans Affairs Health Care System
Palo Alto, CA
Consultant: Curon Medical Inc., TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Curon, Janssen, TAP, Wyeth; Equity: Curon.

Management on Long-Term PPI Therapy
Colin W. Howden, MD, FACG
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
Consultant: Prometheus, Takeda Pharma, TAP; Investigator: TAP, Merck; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Merck, TAP, Wyeth.

IS SCREENING FOR BARRETT'S ESOPHAGUS NECESSARY?
Good Evidence for Screening
Roy K.H. Wong, MD, FACG
Professor of Medicine
Director of the Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Bethesda, MD
Grant Support: ACG, AstraZeneca, Janssen.

Screenings Not Cost-Effective
Dawn Provenzale, MD
Associate Professor & Director of GI Outcomes Research
Duke University Medical Center
Durham, N.C.
Nothing to disclose.

ENDOSCOPY-NEGATIVE REFLUX DISEASE: ACID-RELATED DISORDER OR FUNCTIONAL DISORDER?
Endoscopy-Negative Reflux Disease Is an Acid-Related Disorder
Joel E. Richter, MD
Professor of Medicine and Chairman
Department of Gastroenterology and Hepatology
Cleveland Clinic Foundation
Cleveland, OH
Consultant: AstraZeneca, TAP; Speakers' Bureau: AstraZeneca, Janssen, TAP, Wyeth.

Endoscopy-Negative Reflux Disease Is a Functional Disorder
William D. Chey, MD, FACG, FACP
Associate Professor of Medicine
Director of GI Physiology Laboratory
University of Michigan
Ann Arbor, MI
Consultant: AstraZeneca, TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Janssen Pharmaceutica, Inc., TAP.

A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.

To view the supplement, click the image above.

INTRODUCTION
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Centre
Hamilton, Ont.
Consultant: Abbott Laboratories, Axcan Pharma Inc., AstraZeneca, Merck & Co., Novartis Pharmaceuticals Corp., Procter & Gamble Co., TAP Pharmaceutical Products, Inc.; Investigator: Axcan, AstraZeneca, Merck, TAP.

USE OF NONSELECTIVE NSAIDS, CYCLOOXYGENASE INHIBITORS, AND PROTON PUMP INHIBITORS
Treat With Nonselective NSAIDs, plus PPIs
Michael B. Kimmey, MD
Professor of Medicine and Director of Gastrointestinal Endoscopy
University of Washington
Seattle, WA
Nothing to disclose.

Treat With Cyclooxygenase Inhibitors
Jay L. Goldstein, MD
Professor of Medicine
Vice Head for Clinical Affairs
Department of Medicine
University of Illinois
Chicago, IL
Consultant & Grant Support: AstraZeneca, Pharmacia Corp., Pfizer Inc., TAP.

OPTIONS IN THE LONG-TERM MAINTENANCE OF GASTROESOPHAGEAL REFLUX DISEASE
Endoscopic/Surgical Intervention
George Triadafilopoulos, MD
Professor of Medicine
Stanford University School of Medicine
Chief, Section of Gastroenterology
Palo Alto Veterans Affairs Health Care System
Palo Alto, CA
Consultant: Curon Medical Inc., TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Curon, Janssen, TAP, Wyeth; Equity: Curon.

Management on Long-Term PPI Therapy
Colin W. Howden, MD, FACG
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
Consultant: Prometheus, Takeda Pharma, TAP; Investigator: TAP, Merck; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Merck, TAP, Wyeth.

IS SCREENING FOR BARRETT'S ESOPHAGUS NECESSARY?
Good Evidence for Screening
Roy K.H. Wong, MD, FACG
Professor of Medicine
Director of the Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Bethesda, MD
Grant Support: ACG, AstraZeneca, Janssen.

Screenings Not Cost-Effective
Dawn Provenzale, MD
Associate Professor & Director of GI Outcomes Research
Duke University Medical Center
Durham, N.C.
Nothing to disclose.

ENDOSCOPY-NEGATIVE REFLUX DISEASE: ACID-RELATED DISORDER OR FUNCTIONAL DISORDER?
Endoscopy-Negative Reflux Disease Is an Acid-Related Disorder
Joel E. Richter, MD
Professor of Medicine and Chairman
Department of Gastroenterology and Hepatology
Cleveland Clinic Foundation
Cleveland, OH
Consultant: AstraZeneca, TAP; Speakers' Bureau: AstraZeneca, Janssen, TAP, Wyeth.

Endoscopy-Negative Reflux Disease Is a Functional Disorder
William D. Chey, MD, FACG, FACP
Associate Professor of Medicine
Director of GI Physiology Laboratory
University of Michigan
Ann Arbor, MI
Consultant: AstraZeneca, TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Janssen Pharmaceutica, Inc., TAP.

A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.

To view the supplement, click the image above.

INTRODUCTION
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Centre
Hamilton, Ont.
Consultant: Abbott Laboratories, Axcan Pharma Inc., AstraZeneca, Merck & Co., Novartis Pharmaceuticals Corp., Procter & Gamble Co., TAP Pharmaceutical Products, Inc.; Investigator: Axcan, AstraZeneca, Merck, TAP.

USE OF NONSELECTIVE NSAIDS, CYCLOOXYGENASE INHIBITORS, AND PROTON PUMP INHIBITORS
Treat With Nonselective NSAIDs, plus PPIs
Michael B. Kimmey, MD
Professor of Medicine and Director of Gastrointestinal Endoscopy
University of Washington
Seattle, WA
Nothing to disclose.

Treat With Cyclooxygenase Inhibitors
Jay L. Goldstein, MD
Professor of Medicine
Vice Head for Clinical Affairs
Department of Medicine
University of Illinois
Chicago, IL
Consultant & Grant Support: AstraZeneca, Pharmacia Corp., Pfizer Inc., TAP.

OPTIONS IN THE LONG-TERM MAINTENANCE OF GASTROESOPHAGEAL REFLUX DISEASE
Endoscopic/Surgical Intervention
George Triadafilopoulos, MD
Professor of Medicine
Stanford University School of Medicine
Chief, Section of Gastroenterology
Palo Alto Veterans Affairs Health Care System
Palo Alto, CA
Consultant: Curon Medical Inc., TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Curon, Janssen, TAP, Wyeth; Equity: Curon.

Management on Long-Term PPI Therapy
Colin W. Howden, MD, FACG
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
Consultant: Prometheus, Takeda Pharma, TAP; Investigator: TAP, Merck; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Merck, TAP, Wyeth.

IS SCREENING FOR BARRETT'S ESOPHAGUS NECESSARY?
Good Evidence for Screening
Roy K.H. Wong, MD, FACG
Professor of Medicine
Director of the Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Bethesda, MD
Grant Support: ACG, AstraZeneca, Janssen.

Screenings Not Cost-Effective
Dawn Provenzale, MD
Associate Professor & Director of GI Outcomes Research
Duke University Medical Center
Durham, N.C.
Nothing to disclose.

ENDOSCOPY-NEGATIVE REFLUX DISEASE: ACID-RELATED DISORDER OR FUNCTIONAL DISORDER?
Endoscopy-Negative Reflux Disease Is an Acid-Related Disorder
Joel E. Richter, MD
Professor of Medicine and Chairman
Department of Gastroenterology and Hepatology
Cleveland Clinic Foundation
Cleveland, OH
Consultant: AstraZeneca, TAP; Speakers' Bureau: AstraZeneca, Janssen, TAP, Wyeth.

Endoscopy-Negative Reflux Disease Is a Functional Disorder
William D. Chey, MD, FACG, FACP
Associate Professor of Medicine
Director of GI Physiology Laboratory
University of Michigan
Ann Arbor, MI
Consultant: AstraZeneca, TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Janssen Pharmaceutica, Inc., TAP.